SNP polymorphism of LGALS3BP gene in patients with benign and malignant thyroid tumours;Polimorfizmy typu SNP w obrȩbie genu LGALS3BP u chorych z łagodnymi i złośliwymi nowotworami tarczycy

Endokrynologia Polska

Volumn 57, Issue SUPPL.A, 2006, Pages

  Łukieńczuk, Tadeusz ^a   Kaliszewski, Krzysztof ^a   Zołȩdziewska, Magdalena ^a   Jonkisz, Anna ^a   Dmochowska, Grazyna ^a   Dobrut, Mirosław ^b   Rogoliński, Jacek ^b   Dobosz, Tadeusz ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Follicular adenomas; LGALS3BP gene; Nodular goiter; Single nucleotide polymorphism (SNP); Thyroid cancer

Indexed keywords

CARRIER PROTEIN; GLYCOPROTEIN; LGALS3BP PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ADENOMA; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; COMPARATIVE STUDY; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; NODULAR GOITER; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID TUMOR;

ADENOMA; ADULT; AGED; ANTIGENS, NEOPLASM; CARRIER PROTEINS; CASE-CONTROL STUDIES; FEMALE; GLYCOPROTEINS; GOITER, NODULAR; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79958269896     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Kadrofske M, Openo P, Wang L. The human LGALS3 (galectin-3) gene: determination of the gene structure and functional characterization of the promoter. Arch Biochem Biophys 1998; 349 (1): 7-20.
2. Feilcheenfeldt J, Tutsch, Sien-Yi Shen i wsp. Expression of galectin-3 in normal and malignant thyroid tissue by quantitative PCR and immunohistochemistry. Modern Pathology 2003; 16 (11): 1117-1123.
3. Cvejic D, Savin S, Petrovic I i wsp. Differential expression of galectin-3 in papillary projections of malignant and non-malignant hyperplastic thyroid lesions. Acta Chir Iugosl 2003; 50 (3): 67-70.
4. Kovacs R, Foldes J, Winkler G i wsp. The investigation of galectin-3 in diseases of the thyroid gland. Eur J Endocrinol 2003; 149 (5): 449-453.
5. Kawachi K, Matsushita Y, Yonezawa S i wsp. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Human Pathology 2000; 31 (4): 428-433.
6. Huang Y, Prasad M, Lemon W. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA 2001; 98: 15044-15049.
7. Steffen J. Uwarunkowania dziedziczne w zachorowaniach na raka tarczycy. Endokrynol Pol 1995; 46 (supl. 2): 9-10.
8. Ła̧cka K. Podstawy molekularne nowotworów złośliwych tarczycy. Endokrynol Pol 1995; 46 (supl. 2): 29-39.
9. Trupp M, Arena E, Fainzilber M. Functional receptor for GDNF encoded by the c-RET oncogene. Nature 1996; 381: 785-793.
10. Wiench M, Kwaśniewski M, Gubała E. Mutacje somatyczne protoonkogenu RET w raku rdzeniastym tarczycy. Wiad Lek 2001; 54 (supl. 1): 415-421.
11. Wiench M, Włoch J, Oczko M. Rearanżacje genu RET w raku brodawkowatym tarczycy. Wiad Lek 2001; 54 (supl. 1): 64-71.
12. Lewiński A, Ferenc T, Sporny S, Jarza̧b B. Thyroid carcinoma: diagnostic and therapeutic approach: genetic background (review). Endocinol Regul 2000; 34: 99-113.
13. Soda G, Antonaci A, Bosco D. Expession of bcl-2, c-erB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas. J Exp Clin Cancer Res 1999; 18: 363-367.
14. Freeman J, Carroll C, Asa S, Ezzat S. Genetic events in the evolution of thyroid cancer. J Otolaryngol 2002; 31: 202-206.
15. Farid N. P53 mutations in thyroid carcinoma: tidings from and old foe. J Endocrinol Invest 2001; 24: 536-545.
16. Li H, Chen XL, Li HQ. Polymorphism of CYPIA1 and GSTN1 genes associated with susceptibility of gastric cancer in Shandong Province of China. World J Gastroenterol 2005; 11: 5757-5762.
17. Zhang Y, Lang Q, Rothman N i wsp. A putative exonic splicing polymorphism in the BCL 6 gene and risk of non-Hodgkin lymphoma. J Natl Cancer Inst 2005; 97: 1616-1618.
18. Zhu Q, Bian JC, Shen Q i wsp. Genetic polymorphism in X-ray crosscomplementing gene 1 and susceptibility to papillary thyroid carcinoma. Zhonghua Liu Xing Bing Xue Za Zhi 2004; 25: 702-705.
19. McLeod HL. Pharmacogenetic analysis of clinically relevant genetic polymorphisms. Clin Infect Dis 2005; supl. 7: 449-452.
20. Baumgartner-Parzer SM, Lang R, Wagner L i wsp. Polymorphism in exon 13 and intron 14 of RET proto-oncogene: Genetic modifiers of medullary thyroid carcinoma? J Clin Endocrinol Metab 2005; 90: 6232-6236.